Targeting Stem Cells in Chronic Myeloid Leukemia with a PPAR-γ Agonist.
Combining a tyrosine kinase inhibitor (imatinib) and a thiazolidinedione (pioglitazone) is proposed for the treatment of chronic myeloid leukemia.